Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus

Cited by (452)

Items 401–452 of 452

1. Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
   Muhammad Afzal, Fahad Ahmed Al-Abbasi, Muhammad Shahid Nadeem, Sultan Alshehri, Mohammed M. Ghoneim, Syed Sarim Imam, Waleed Hassan Almalki, Imran Ahmed Kazmi · 2021 · Metabolites
2. CKD-MBD und sekundärer Hyperparathyreoidismus (Teil 2)
   Kai M. Hahn, Markus Ketteler · 2021 · Dialyse aktuell
3. Osteoporosis/bone fragility
   Nicola Napoli · 2021 · Journal of Gerontology and Geriatrics
4. Type 2 Diabetes and Bone
   Se‐Min Kim, Lena Fan, Mishaela Ruth Rubin · 2022 · Springer eBooks
5. Pathogenesis: Hemodynamic Alterations
   María José Soler, Conxita Jacobs-Cachá, Manga Motrapu, Hans‐Joachim Anders · 2022 · Springer eBooks
6. Treating Type 2 Diabetes Mellitus
   Alexandra L. Migdal, Susan Herzlinger, Martin J. Abrahamson · 2017 · Springer eBooks
7. Treating Type 2 Diabetes Mellitus
   Alexandra L. Migdal, Susan Herzlinger, Martin J. Abrahamson · 2017 · Springer eBooks
8. Treating Type 2 Diabetes Mellitus
   Alexandra L. Migdal, Martin J. Abrahamson · 2016 · Springer eBooks
9. Faculty Opinions recommendation of Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study).
   Wilbert S. Aronow · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
10. Comparative evaluation of Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors influence on bone turnover markers in rats with experimental type 2 diabetes mellitus
    Н. В. Тимкина, А. В. Симаненкова, Т. Л. Каронова, Timur Dmitrievich Vlasov, N. Yu. Semenova, А. А. Байрамов, В. А. Тимофеева, Anzhelika Shimshilashvili, Evgeny V. Shlyakhto · 2022 · Osteoporosis and Bone Diseases
11. Antiglycemic Agents
    Lee‐Shing Chang, Matthew I. Kim · 2016 · Hospital Medicine Clinics
12. Posttransplant Bone Loss
    Se‐Min Kim, Lubna Bashir Munshi, Bateel Alamoush, Mone Zaidi, Sol Epstein · 2020 · Elsevier eBooks
13. Canagliflozin increases risk of fractures
    2015 · Reactions Weekly
14. Review on sodium glucose co-transporter-2 inhibitors for treatment of type-2 diabetes mellitus
    Jyotishman Mukhopadhyay · 2022 · GSC Biological and Pharmaceutical Sciences
15. Glucose-Lowering Drugs and Fracture Risk among Diabetics: Review Article
    Nema Abd El-Wanees Abd El-Shafy, Hamed Abdelaziz Deraz, Atef Goda Hussein, Mostafa Mohamad Assy · 2022 · The Egyptian Journal of Hospital Medicine
16. New Drugs for Type 2 Diabetes: New Hopes and New Concerns About the Skeleton
    Zehra Berberoğlu · 2016 · EMJ Oncology
17. Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity score-matched study with competing risk analysis
    Oscar Hou In Chou, Jiandong Zhou, Danish Iltaf Satti, Jonathan V Mui, Karen Lin, Sharen Lee, Wing Tak Wong, Abraham Ka Chung Wai, Tong Liu, Bernard M.Y. Cheung et al. · 2023 · medRxiv
18. Are Sodium-Glucose Cotransporter–2 (SGLT2) Inhibitors related to falls in cardiometabolic patients? An European Pharmacovigilance Analysis
    Annamaria Mascolo, Concetta Rafaniello, Donatella Ruggiero, Maria Rosaria Campitiello, Maria Donniacuo, Pasquale Maria Berrino, Francesco Rossi, Giuseppe Paolisso, Annalisa Capuano · 2023 · Research Square
19. An update on the role of antihyperglycemic agents in diabetoporosis
    Nidhi Sharma, Amit Kumar Nayak · 2023 · Journal of Diabetology
20. Highlights from the Diabetes UK Professional Conference 2023
    Katherine Bishop · 2023 · Prescriber
21. Inibitori del cotrasportatore sodio-glucosio di tipo 2 in pazienti sottoposti a trapianto renale
    Aris Tsalouchos · 2023 · Giornale di Clinica Nefrologica e Dialisi
22. Clinical effects of Sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes
    Qin He, Jun Zeng, Jianming Yang, Renmin Tang, Wen Wang · 2023 · Research Square
23. Type 2 diabetes beyond glycaemic control
    Nikki C. C. Werkman · 2023
24. A New Age for Secondary Prevention: Optimal Medical Therapy for Stable Ischemic Heart Disease Among Patients with Diabetes and/or Obesity
    Nkiru Osude, Neha Jadeja Pagidipati · 2023 · Medical Clinics of North America
25. Clinical risk factors analysis and prevention of osteoporosis as a complication of diabetes
    Jiaojiao Wang, Hang Li, Haihong Zhu, Xinyan Xie, Qiyue Zheng, Jian Qu, Haiyan Yuan, Ting Liu, Qiong Lu · 2023 · International Journal of Diabetes in Developing Countries
26. The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review
    Vikri Haikal, Soebagijo Adi Soelistijo, Puspa, Jongky Hendro Prajitno · 2024 · Current Internal Medicine Research and Practice Surabaya Journal
27. A Study of the Treatment of Osteoporosis in Type 2 Diabetes Mellitus
    靖威 郑 · 2024 · Advances in Clinical Medicine
28. SGLT2 Inhibitors for Primary and Secondary Protection from Cardiovascular and Renal Diseases in Type 2 Diabetes
    Mukesh Nandave · 2024 · Springer eBooks
29. A comprehensive Review of Preclinical and Clinical Information on the Cardiovascular Advantages of SGLT2 Inhibitors
    Mukesh Nandave · 2024 · Springer eBooks
30. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT-2i) in Lupus Nephritis
    Abire Allaoui, Rita Aniq Filali, Amine Khalfaoui, Abdelhamid Naitlho · 2024 · IntechOpen eBooks
31. The Mechanisms of Diabetes Mellitus-Induced Osteoporosis, Bone Quality Risk Assessment, and Advances in Treatment
    馨 杨 · 2025 · Advances in Clinical Medicine
32. Research Progress in Fracture Risk Assessment and Treatment for T2DM Complicated with Osteoporosis
    诗怡 刘 · 2025 · Advances in Clinical Medicine
33. Bone Fragility in Diabetes: Insights into Mechanisms and Therapeutic Strategies
    Malak Faraj, Nicola Napoli · 2025 · Springer eBooks
34. Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013-2024): a pharmacovigilance study.
    Marya Ahsan · 2025 · Naunyn-Schmiedeberg's Archives of Pharmacology
35. Impact of dapagliflozin on bone mineral metabolism in non-diabetic patients with chronic kidney disease: a randomized, double-blind, placebo-controlled study
    Mohamed Elshayeb, Ahmed Elsaeed Abdulgalil, Amr A El-Husseini, Muhammed Ahmed Elhadedy, Samir M. Sally, Huda Refaie, Wael Ibrahim Mortada, Kareem A. Nabieh, Mohamed Sobh · 2025 · Clinical Kidney Journal
36. Additional file 1 of Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Wang, Jing, Xin Li, Yang Li, Chen Lei · 2024 · Figshare
37. Additional file 1 of The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT)
    Ai Haraguchi, Riyoko Shigeno, Ichiro Horie, Shimpei Morimoto, Ayako Ito, Chiba, Ko, Yurika Kawazoe, Shigeki Tashiro, Junya Miyamoto, Sato, Shuntaro et al. · 2020 · Figshare
38. Additional file 4 of Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
    Giulia Ferrannini, Norman R Rosenthal, Michael K. Hansen, Ferrannini, Ele · 2022 · Figshare
39. Brazilian guidelines for the management of osteoporosis in diabetes mellitus
    F Albuquerque de Paula, Bárbara Campolina C. Silva, Catarina Brasil d’Alva, Monique Nakayama Ohe, Miguel Madeira, Leonardo Bandeira e Farias, Narriane Chaves Pereira de Holanda, Neuton Dornelas Gomes, Ruy Lyra da Silva Filho, Márcio Weissheimer Lauria et al. · 2025 · Diabetology & Metabolic Syndrome
40. Sodium Glucose Transport Protein-2 (SGLT-2) Inhibitors
    Dorothy Jung, Omaima Ali · 2026 · Springer eBooks
41. How to treat a diabetic patient with osteoporosis
    Peter Jackuliak, Magdaléna Kovářová, Martin Kužma, Zdenko Killinger, Juraj Payer · 2020 · Clinical Osteology
42. Type 2 diabetes mellitus and bone quality
    Ivan Raška · 2018 · Clinical Osteology
43. Commentary on “Association between frailty index and hip fracture among Chinese middle- and old-aged adults in different glycemic status: a prospective study from the China health and retirement longitudinal study (CHARLS)”
    Xiaohan Liu, Qian Zhang, Xiangji Liu · 2026 · International Journal of Surgery
44. From molecules to the clinic—pathophysiology of sodium-glucose cotransporter 2 inhibitors and their emerging role in urology: A comprehensive review from the European Association of Urology Section of Endourology
    A. Talyshinskii, V. Gauhar, Steffi Kar Kei Yuen, Selçuk Güven, T. Tokas, A. Tsaturyan, Dmitry Enikeev, B. Somani · 2026 · Asian Journal of Urology
45. Classical homeostatic physiology sheds light on vitamin D controversies
    Simeon I. Taylor, Zhinous Shahidzadeh Yazdi · 2026 · Trends in Endocrinology and Metabolism
46. Indicaciones de los fármacos iSGLT2
    Mariona Nadal Llover, Montse Cols Jiménez, Yaiza Ortuño Ruíz · 2026 · FMC - Formación Médica Continuada en Atención Primaria
47. Insights from Secular Trend of Major Osteoporotic Fractures in People with and without Diabetes: 15-Year Population-based Study (2009–2023)
    David Tak Wai Lui, Xincheng Zou, Chi‐Ho Lee, Wing-Sun Chow, Carol H.Y. Fong, Mstat; Chloe Y.Y. Cheung, Ka Shing Cheung, Andrew Y. Y. Ho, Benjamin Yick Toa Au Yeung, Tin-Wai Wong et al. · 2026 · Endocrine Practice
48. Molecular and clinical mechanisms of renal protection by SGLT2 inhibitors: a comprehensive review
    Berthold Hocher, Carl‐Friedrich Hocher, Saban Elitok · 2026 · Current Opinion in Physiology
49. Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis
    Lauter Eston Pelepenko, Joaquim Barreto, Mônica Martins, Pedro Bonifácio Chiteculo, Jéssica Victor de CAMARGO, Mariana Cassani de Oliveira, Eric Aragão Corrêa, Mauro Alexandre Páscoa, Gil Guerra‐Júnior, Wagner Vasques Dominguez et al. · 2026 · Calcified Tissue International
50. Assessment of monotherapy and combination therapy with canagliflozin, metformin, and fenugreek seed extract in experimental diabetic osteopathy
    Faiz Qamar, Shirin Sultana, Mohd Vaseem, Tufail Ahmad, Manju Sharma · 2026 · 3 Biotech
51. Association Between Glycemic Variability and Bone Turnover and the Sema3A Signaling Pathway in Postmenopausal Women with Type 2 Diabetes Mellitus
    Burcu Cosgun Bora, Sertaş Erarslan · 2026 · Metabolites
52. Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects
    Sam Woodworth, Robert Hayden · 2026 · Journal of Brown Hospital Medicine